Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qilong Sanjie is a Traditional Chinese Medicine (TCM) formulation, typically administered as a capsule, developed by Shandong Provincial Hospital Affiliated to Shandong First Medical University. It is primarily investigated for the treatment of "gall disease" (Ying Bing), which in Western medicine corresponds to thyroid disorders such as hyperthyroidism and Graves' disease. The formulation is specifically indicated for patients presenting with the TCM syndrome of phlegm and blood stasis. Qilong Sanjie aims to resolve nodules, dissipate masses (Sanjie), and regulate thyroid function by addressing the underlying TCM pathologies of phlegm accumulation and blood stasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on qilong sanjie.